Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential ... Allarity Therapeutics A/SJanuary 26, 2021 GMT Press Release Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the “British variant”), at the Pathogen and Microbiome Institute at No...